[Federal Register: October 29, 2003 (Volume 68, Number 209)] [Notices] [Page 61699] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr29oc03-61] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Application Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on August 6, 2003, Guilford Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of cocaine (9041) a basic class of controlled substance listed in Schedule II. The firm plans to manufacture a Schedule II cocaine derivative as a final intermediate for the production of dopascan injection. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration. Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than [December 29, 2003]. Dated: October 7, 2003. Laura M. Nagel, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 03-27240 Filed 10-28-03; 8:45 am] BILLING CODE 4410-09-M